44 growth-stage biotech investors in the US
We list 44 growth-stage biotech investors in the US as of November 2026: each has an SEC filing on file, and the list was last checked on 6 Nov 2026. The cities with the most head offices on this list are New York (7), Menlo Park (3) and Boston (3).
Top 5 growth-stage biotech investors in the US, ranked by recent fund activity
Among firms with a published profile and a dated fund or deal in the last 24 months. The rule: Activity score out of 100: recency of the latest fund filing or dated deal (30: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (20; half of that when the sector is stated only), stage focus (15: all of it when growth-stage is the only stage the firm states, split evenly when it states more), stated focus on the US (15: full marks when the firm names the US as where it invests, half when it says global), size of the fund on file on a log scale (12) and completeness of the public record (8). Stage and regional focus are our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns. The same rule orders the whole list; it is repeated in the method box.
Longitude Venture Partners
Type: VC firm · HQ: Menlo Park, CA · Stages: Growth · Focus: Biotech, Healthtech, Medtech · Latest activity: New deal, Jun 2026 · Fund size on file: $600M (SEC Form D, 2022)
Dated new deal in Jun 2026; $600M fund on file (SEC Form D, 2022); 80% of its observed portfolio is biotech and life sciences; backs growth-stage; names the US as where it invests; 8 named decision-makers on file.
MVM Partners LLP
Type: VC firm · HQ: Boston, MA · Stages: Growth · Focus: Biotech, Healthtech, Medtech · Latest activity: Portfolio news, Jun 2026 · Private fund assets: $1.0B (SEC Form ADV)
Portfolio news dated Jun 2026; $1.0B on file (SEC Form ADV); states biotech and life sciences as a focus; backs growth-stage; names the US as where it invests.
JSTAR Capital
Type: VC firm · HQ: Austin, TX · Stages: Growth · Focus: Biotech, Healthtech, AI, Fintech · Latest activity: New fund, Aug 2026 · Fund size on file: $100M (SEC Form D, 2025)
Latest fund filing dated Aug 2026; $100M fund on file (SEC Form D, 2025); 25% of its observed portfolio is biotech and life sciences; backs growth-stage; 8 named decision-makers on file.
Madrona
Type: VC firm · HQ: Seattle, WA · Stages: Pre-seed, Seed, Series A, Series B, Growth · Focus: Biotech, AI, Consumer, Deep Tech · Latest activity: New deal, Oct 2026 · Fund size on file: $490M (SEC Form D, 2025)
Dated new deal in Oct 2026; $490M fund on file (SEC Form D, 2025); states biotech and life sciences as a focus; backs pre-seed, seed, Series A; names the US as where it invests; 8 named decision-makers on file.
NewVale Capital
Type: VC firm · HQ: Boulder, CO · Stages: Growth · Focus: Biotech, Healthtech, Medtech · Latest activity: New fund, Oct 2026 · Fund size on file: $250M (SEC Form D, 2026)
Latest fund filing dated Oct 2026; $250M fund on file (SEC Form D, 2026); states biotech and life sciences as a focus; backs growth-stage; 8 named decision-makers on file.
First 22 of 44 growth-stage biotech investors in the US
| Investor | Type | HQ | Stagesour research | Focusour research | Latest fund or deal | Fund sizeas filed or stated | Checked | Contacts |
|---|---|---|---|---|---|---|---|---|
| Longitude Venture Partners | VC firm | Menlo Park, CA | Growth | Biotech, Healthtech, Medtech | New deal, Jun 2026 | $600M (SEC Form D, 2022) | 5 Nov 2026 | 8 names · Unlock |
| MVM Partners LLP | VC firm | Boston, MA | Growth | Biotech, Healthtech, Medtech | Portfolio news, Jun 2026 | $1.0B (SEC Form ADV) | 5 Nov 2026 | No contact on file |
| JSTAR Capital | VC firm | Austin, TX | Growth | Biotech, Healthtech, AI, Fintech | New fund, Aug 2026 | $100M (SEC Form D, 2025) | 4 Nov 2026 | 8 names · Unlock |
| Madrona | VC firm | Seattle, WA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Consumer, Deep Tech | New deal, Oct 2026 | $490M (SEC Form D, 2025) | 5 Nov 2026 | 8 names · Unlock |
| NewVale Capital | VC firm | Boulder, CO | Growth | Biotech, Healthtech, Medtech | New fund, Oct 2026 | $250M (SEC Form D, 2026) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Audere | VC firm | Austin, TX | Growth | Biotech, Cybersecurity, AI, Robotics | New fund, Oct 2026 | $100M (SEC Form D, 2024) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Arcventis Health Partners | VC firm | New York, NY | Growth | Biotech, Healthtech, Medtech | New fund, Sep 2026 | $33M (SEC Form D, 2025) | 4 Nov 2026 | 4 names, firm email · Unlock |
| THP | VC firm | San Francisco, CA | Growth | Biotech, Healthtech, Industrial Tech, Medtech | Portfolio news, Apr 2026 | $79M (SEC Form D, 2022) | 5 Nov 2026 | 1 name, firm email · Unlock |
| Eckuity Capital | VC firm | New York, NY | Growth | Biotech, Healthtech, Medtech | New fund, Jun 2026 | $300M (SEC Form D, 2026) | 4 Nov 2026 | 1 name · Unlock |
| BroadOak Capital Partners | VC firm | Bethesda, MD | Growth | Biotech, Healthtech, Industrial Tech, SaaS | Portfolio news, Apr 2026 | $11M (SEC Form D, 2021) | 5 Nov 2026 | 8 names · Unlock |
| K5 Global | VC firm | Miami Beach, FL | Pre-seed, Growth, Any stage | Biotech, AI, Fintech, Healthtech | New fund, Oct 2026 | $10M (SEC Form D, 2026) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Signet Healthcare Partners | VC firm | New York, NY | Growth | Biotech, Industrial Tech, Developer Tools, Healthtech | Portfolio news, May 2025 | $300M (SEC Form D, 2022) | 5 Nov 2026 | 8 names · Unlock |
| Agent Capital | VC firm | Waltham, MA | Seed, Growth | Biotech, Healthtech | New fund, Feb 2026 | $100M (SEC Form D, 2021) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Andreessen Horowitz (a16z) | VC firm | Menlo Park, CA | Seed, Series A, Series B, Growth | Biotech, AI, Defense Tech, Healthtech | New fund, Aug 2026 | 4 Nov 2026 | 2 names · Unlock | |
| Richmond Global | VC firm | Las Vegas, NV | Growth | Biotech, AI, Cybersecurity, Govtech | $116M (SEC Form ADV) | 5 Nov 2026 | 3 names · Unlock | |
| Accelmed | VC firm | Aventura, FL | Growth | Biotech, Healthtech, Developer Tools, Medtech | Portfolio news, Apr 2026 | $401M (SEC Form D, 2021) | 5 Nov 2026 | 8 names, firm email · Unlock |
| B Capital | VC firm | Manhattan Beach, CA | Seed, Series A, Series B, Growth | Biotech, AI, Fintech, Healthtech | New fund, Jul 2025 | $307M (SEC Form D, 2023) | 4 Nov 2026 | 8 names, firm email · Unlock |
| DC Global Ventures | VC firm | Menlo Park, CA | Seed, Growth | Biotech, Healthtech, Industrial Tech, Medtech | $2.7B (SEC Form ADV) | 5 Nov 2026 | 8 names · Unlock | |
| NW Angel Fund | VC firm | Seattle, WA | Growth | Biotech, Healthtech, SaaS, Medtech | New fund, Feb 2024 | $5M (SEC Form D, 2024) | 5 Nov 2026 | 2 names · Unlock |
| Antler | Accelerator | New York, NY | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Healthtech, Consumer | New deal, Aug 2026 | $90M (SEC Form D, 2023) | 4 Nov 2026 | 8 names · Unlock |
| Apple Tree Venture | VC firm | New York, NY | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech | Portfolio news, Sep 2025 | $3.5B (SEC Form ADV) | 5 Nov 2026 | 8 names, firm email · Unlock |
| Frazier Life Sciences | VC firm | Palo Alto, CA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech | New fund, Mar 2025 | $7.0B (SEC Form ADV) | 5 Nov 2026 | 6 names · Unlock |
You are seeing 22 of 44. The full list adds 22 more investors and 251 named decision-makers.
One-time payment. No subscription. No account.
Or get the free sample.
How these 44 break down
By US state
| US state | On this list | Share |
|---|---|---|
| California | 11 | 25% |
| New York | 7 | 16% |
| Massachusetts | 5 | 11% |
| Texas | 3 | 7% |
| Florida | 3 | 7% |
| Connecticut | 3 | 7% |
| Washington | 2 | 5% |
| Maryland | 2 | 5% |
| Iowa | 2 | 5% |
By type
| Type | On this list | Share |
|---|---|---|
| VC firm | 41 | 93% |
| Accelerator | 1 | 2% |
| Corporate VC | 1 | 2% |
| Government or university fund | 1 | 2% |
Method and limits
- Source
- All 44 rows carry an SEC filing (Form D or Form ADV). All 44 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule
- Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at growth-stage.
- Order
- Firms with a published profile come first. Activity score out of 100: recency of the latest fund filing or dated deal (30: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (20; half of that when the sector is stated only), stage focus (15: all of it when growth-stage is the only stage the firm states, split evenly when it states more), stated focus on the US (15: full marks when the firm names the US as where it invests, half when it says global), size of the fund on file on a log scale (12) and completeness of the public record (8). Stage and regional focus are our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Last refreshed
- November 2026. Rows on this list were checked between 4 Nov 2026 and 6 Nov 2026.
- Fill rates
- Of 44 rows: stage 44, sector 44, fund size 39, website 44. In the paid file: named decision-makers on 42 rows, firm email on 17, LinkedIn page on 21, check size on 3.
- Corrections
- Email hello@theinvestordatabase.com or use the update form. We act within 5 working days.
Questions
How many growth-stage biotech investors in the US are there?
We list 44 as of November 2026. 23 of the 44 have a fund filing or a dated deal in the last 12 months. The cities with the most are New York (7), Menlo Park (3) and Boston (3).
Which growth-stage biotech investors in the US raised a new fund in the last 12 months?
15 of the 44 have a fund filing dated in the last 12 months. The most recent on this list are Audere (Oct 2026), K5 Global (Oct 2026) and NewVale Capital (Oct 2026).
What is the typical fund size of growth-stage biotech investors in the US?
The median fund size on file for this list is $100M, across the 26 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 18 do not disclose a size there.
How do I contact growth-stage biotech investors in the US?
The paid file holds 251 named decision-makers across 42 of these 44 and a firm email for 17. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.
Where does the data on growth-stage biotech investors in the US come from?
All 44 rows have an SEC filing on file (Form D or Form ADV). Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 6 Nov 2026 at the latest. The whole file is re-verified twice a year.
Broader lists
Biotech venture capital firms in the US (297)Growth-stage investors in the US (288)Growth-stage biotech investors (109)
Related lists
Growth-stage AI investors in the US (162)Growth-stage SaaS investors in the US (162)Seed biotech investors in the US (159)Growth-stage healthtech investors in the US (121)Growth-stage fintech investors in the US (97)Pre-seed biotech investors in the US (81)Growth-stage medtech investors in the US (69)Growth-stage consumer investors in the US (60)Series A biotech investors in the US (59)Growth-stage cybersecurity investors in the US (55)Growth-stage B2B investors in the US (54)Growth-stage deep tech investors in the US (43)Growth-stage energy investors in the US (42)Growth-stage hardware investors in the US (36)Growth-stage industrial tech investors in the US (35)Series B biotech investors in the US (34)Growth-stage climate tech investors in the US (34)Growth-stage developer tools investors in the US (24)
Not sure this is the right list? Describe your raise in the investor matching tool and get a shortlist. The link opens it set to biotech and life sciences, growth-stage and the US. Guide: how many investors to pitch. Markdown version of this page.
Check the quality first
A free sample of 100 investors, every column, with sources and dates.